

# Daniel H Ahn

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2471845/publications.pdf>

Version: 2024-02-01

30  
papers

526  
citations

687363  
13  
h-index

677142  
22  
g-index

30  
all docs

30  
docs citations

30  
times ranked

1040  
citing authors

#	ARTICLE	IF	CITATIONS
1	A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma. <i>Investigational New Drugs</i> , 2022, 40, 134-141.	2.6	21
2	Synergistic combination of cytotoxic chemotherapy and cyclinâ€¢dependent kinase 4/6 inhibitors in biliary tract cancers. <i>Hepatology</i> , 2022, 75, 43-58.	7.3	6
3	FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3797-3805.	2.3	4
4	Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy. <i>JCO Precision Oncology</i> , 2022, , .	3.0	11
5	The Continued Struggle for Defining a Role for Radiotherapy in Pancreas Cancer. <i>JAMA Oncology</i> , 2022, 8, 1257.	7.1	6
6	Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?. <i>Seminars in Liver Disease</i> , 2021, 41, 136-141.	3.6	10
7	Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00414.	2.5	17
8	Circulating Cell-Free Tumor DNA in Advanced Pancreatic Adenocarcinoma Identifies Patients With Worse Overall Survival. <i>Frontiers in Oncology</i> , 2021, 11, 794009.	2.8	8
9	The Role of Maintenance Strategies in Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2020, 6, e194489.	7.1	65
10	The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma. <i>BioDrugs</i> , 2020, 34, 349-362.	4.6	33
11	Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States. <i>Pancreas</i> , 2020, 49, 193-200.	1.1	26
12	Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 3495-3507.	7.0	43
13	Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. <i>Pancreatology</i> , 2019, 19, 80-87.	1.1	24
14	Metastatic Neuroendocrine Tumor with Cardiac Involvement Utilizing Multi-Modality Imaging. <i>Korean Circulation Journal</i> , 2019, 49, 557.	1.9	1
15	AJCC 8th edition staging system for pathologically versus clinically staged intrahepatic cholangiocarcinoma (iCCA): ready for prime time?. <i>Chinese Clinical Oncology</i> , 2019, 8, S19-S19.	1.2	1
16	Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma. <i>Future Oncology</i> , 2018, 14, 553-566.	2.4	22
17	Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer. <i>International Journal of Cancer</i> , 2018, 142, 1671-1675.	5.1	7
18	Emerging role of precision medicine in biliary tract cancers. <i>Npj Precision Oncology</i> , 2018, 2, 21.	5.4	27

#	ARTICLE	IF	CITATIONS
19	Novel immunotherapy strategies for hepatobiliary cancers. Immunotherapy, 2018, 10, 1077-1091.	2.0	6
20	Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma. Cancers, 2018, 10, 193.	3.7	16
21	Secondâ€line treatment in patients with pancreatic ductal adenocarcinoma: A metaâ€analysis. Cancer, 2017, 123, 4680-4686.	4.1	29
22	A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis. Therapeutic Advances in Medical Oncology, 2017, 9, 75-82.	3.2	46
23	The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies. Biomedicines, 2017, 5, 10.	3.2	10
24	Response to Drs Von Hoff and Renschler. Therapeutic Advances in Medical Oncology, 2017, 9, 445-446.	3.2	0
25	Therapeutic options for intrahepatic cholangiocarcinoma. Hepatobiliary Surgery and Nutrition, 2017, 6, 91-100.	1.5	13
26	Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications. Journal of Gastrointestinal Oncology, 2017, 8, 293-301.	1.4	47
27	Oncolytic virotherapy in upper gastrointestinal tract cancers. Oncolytic Virotherapy, 2017, Volume 7, 13-24.	6.0	11
28	A phase II trial of gemcitabine (G), cisplatin (C), and nab-paclitaxel (N) in advanced biliary tract cancers (aBTCs).. Journal of Clinical Oncology, 2017, 35, 4018-4018.	1.6	9
29	Targeting the stroma in pancreatic cancer. Chinese Clinical Oncology, 2017, 6, 65-65.	1.2	7
30	Adjuvant Chemotherapy for Rectal Cancer After Neoadjuvant Treatment: FOLFOX, 5-FU, or Observation. Current Colorectal Cancer Reports, 2016, 12, 260-265.	0.5	0